Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA.
Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA.
Alzheimers Dement. 2023 Jan;19(1):307-317. doi: 10.1002/alz.12797. Epub 2022 Oct 9.
The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. To improve generalizability, ADNI4 aims to enroll 50-60% of its new participants from underrepresented populations (URPs) using new biofluid and digital technologies. ADNI4 has received funding from the National Institute on Aging beginning September 2022.
ADNI4 will recruit URPs using community-engaged approaches. An online portal will screen 20,000 participants, 4000 of whom (50-60% URPs) will be tested for plasma biomarkers and APOE. From this, 500 new participants will undergo in-clinic assessment joining 500 ADNI3 rollover participants. Remaining participants (∼3500) will undergo longitudinal plasma and digital cognitive testing. ADNI4 will add MRI sequences and new PET tracers. Project 1 will optimize biomarkers in AD clinical trials.
ADNI4 will improve generalizability of results, use remote digital and blood screening, and continue providing longitudinal clinical, biomarker, and autopsy data to investigators.
阿尔茨海默病神经影像学倡议（ADNI）旨在验证阿尔茨海默病（AD）临床试验的生物标志物。为了提高普遍性，ADNI4 计划利用新的生物流体和数字技术，从代表性不足的人群（URP）中招募 50-60%的新参与者。ADNI4 从 2022 年 9 月开始获得美国国家老龄化研究所的资助。
ADNI4 将使用社区参与的方法招募 URP。一个在线门户将对 20000 名参与者进行筛选，其中 4000 名（URP 占 50-60%）将接受血浆生物标志物和 APOE 检测。由此，500 名新参与者将接受门诊评估，加入 500 名 ADNI3 结转参与者。其余参与者（约 3500 名）将进行纵向血浆和数字认知测试。ADNI4 将增加 MRI 序列和新的 PET 示踪剂。项目 1 将优化 AD 临床试验中的生物标志物。
ADNI4 将提高结果的普遍性，使用远程数字和血液筛查，并继续向研究人员提供纵向临床、生物标志物和尸检数据。
